Evidence map›Paper›PMID 26798171›Full record

ArticleIndian journal of pharmaceutical sciences

Design, Development and Optimization of S (-) Atenolol Floating Sustained Release Matrix Tablets Using Surface Response Methodology.

P T Gunjal, M B Shinde, V S Gharge, S V Pimple, M K Gurjar, M N Shah

Abstract read
In one paragraph

Article in Indian journal of pharmaceutical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

P T GunjalFormulation and Development Department, Zuventus Healthcare Ltd, T-184 MIDC Bhosari, Pune-411 026, India.
M B ShindeFormulation and Development Department, Zuventus Healthcare Ltd, T-184 MIDC Bhosari, Pune-411 026, India.
V S GhargeEmcure Pharmaceutical Ltd, Emcure House, Pune-411 026, India.
S V PimpleEmcure Pharmaceutical Ltd, Emcure House, Pune-411 026, India.
M K GurjarEmcure Pharmaceutical Ltd, Emcure House, Pune-411 026, India.
M N ShahEmcure Pharmaceutical Ltd, Emcure House, Pune-411 026, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this present investigation was to develop and formulate floating sustained release matrix tablets of s (-) atenolol, by using different polymer combinations and filler, to optimize by using surface response methodology for different drug release variables and to evaluate the drug release pattern of the optimized product. Floating sustained release matrix tablets of various combinations were prepared with cellulose-based polymers: Hydroxypropyl methylcellulose, sodium bicarbonate as a gas generating agent, polyvinyl pyrrolidone as a binder and lactose monohydrate as filler. The 3(2) full factorial design was employed to investigate the effect of formulation variables on different properties of tablets applicable to floating lag time, buoyancy time, % drug release in 1 and 6 h (D1 h,D6 h) and time required to 90% drug release (t90%). Significance of result was analyzed using analysis of non variance and P < 0.05 was considered statistically significant. S (-) atenolol floating sustained release matrix tablets followed the Higuchi drug release kinetics that indicates the release of drug follows anomalous (non-Fickian) diffusion mechanism. The developed floating sustained release matrix tablet of improved efficacy can perform therapeutically better than a conventional tablet.

Indexed as

Buoyancy timefloating lag timefloating sustained releasehydrophilic polymerss (-) atenololsurface response methodology

Identifiers

PMID26798171
PMCPMC4700709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.